Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
• Male or female age between 18-80 years of age, inclusive
* Diagnosed at enrollment (visits 2) to be mild to moderate hypertensive with a MSDBP \>= 95 and =\< 109 mmHg for non treated patients.
* Previously treated patients should have a MSDBP =\< 109 mmHg at visit 1 and a MSDBP \>= 95 and =\< 109 mmHg at visit 2.
* Written informed consent to participate in the study prior to any study procedures
* Ability to communicate and comply with all study requirements
You may not be if
Severe hypertension (grade 3 of WHO classification; \>= 110 mmHg diastolic and/or \>= 180 mmHg systolic).
Malignant hypertension
Inability to discontinue all prior anti-hypertensive medications safely for a period of 2 weeks, as required by the protocol.
Known history of proteinuria (greater than 0.3 gram per day)
Female patients who are not either post-menopausal for one year or surgically sterile, and who are not using effective contraceptive methods such as barrier method with spermicidal or an intra-uterine device. Oral contraceptive use is not allowed.
Known Keith-Wagener grade III or IV hypertensive retinopathy.
History of hypertensive encephalopathy or cerebrovascular accident at anytime prior to Visit 1.
Transient ischemic cerebral attack during the last 12 months prior to Visit 1.
Clareo Health | A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 Mg
